Skip to main content
. 2023 Oct 20;16:2971–2983. doi: 10.2147/CCID.S426972

Figure 3.

Figure 3

Visual treatment effects of IXE at Week 12. (A) Male aged 47 years from Italy; psoriasis for 6 years, bio-naïve, previous systemic conventional therapy, no PsA, diabetes mellitus, overweight, atherosclerosis, dyslipidemia, hypertension and liver disease, initiated IXE as per EMA label at baseline; (B) Female aged 45 from Taiwan; psoriasis for 19 years, bio-experienced, previous systemic conventional therapy, PsA and obesity, switched to IXE as per EMA label at baseline.

Notes: Photographs are subject to Copyright © 2023 Eli Lilly and Company. All rights reserved.

Abbreviations: DLQI, Dermatology Life Quality Index; EMA, European Medicines Agency; IXE, ixekizumab; mNAPSI, Modified Nail Psoriasis Severity Index; NRS, Numeric Rating Scale; PsA, psoriatic arthritis; PASI, Psoriasis Area and Severity Index; PSSD, Psoriasis Signs and Symptoms Diary.